Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod IncfiledCriticalPfizer Prod Inc
Priority to DO2002000513ApriorityCriticalpatent/DOP2002000513A/es
Publication of DOP2002000513ApublicationCriticalpatent/DOP2002000513A/es
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Esta invención se refiere a formas amorfas y cristalinas novedosa de sal mono citrato de 3-{(3R, 4R)-4-metil-3-[metil-3-[metil-(7H-pirrolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-3-oso-propionitrilo de utilidad como inhibidores de proteínas, y a los procedimientos para prepararlas.
Forma cristalina de sal de calcio de acido bis [(e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metilsulfonil)amino]pirimidin-5-il](3r,5s)-3,5-dihidroxihept-6-enoico
A crystalline form of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one
Método para la preparación de 1-((3s,4r)-3-((2-((1-etil-1h-pirazol-4-il)amino)-7h-pirrolo[2,3-d]pirimidin-4-il)oxi)-4-fluoropiperidin-1-il)prop-2-en-1-ona, y sus compuestos intermediarios